Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Tokarska Schlattner, Malgorzata ^a,b   Epand, Raquel F ^c   Meiler, Flurina ^d   Zandomeneghi, Giorgia ^d   Neumann, Dietbert ^d,f   Widmer, Hans R ^e   Meier, Beat H ^d   Epand, Richard M ^c   Saks, Valdur ^a,b   Wallimann, Theo ^d   Schlattner, Uwe ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b INSERM   (France)

^c MCMASTER UNIVERSITY   (Canada)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN; CREATINE KINASE; CREATINE PHOSPHATE; DOXORUBICIN; LIPOSOME; MELITTIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SAPONIN;

ANIMAL CELL; ARTICLE; CHEMICAL BINDING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; HEMOLYSIS; HYPOOSMOTIC STRESS; LIPID COMPOSITION; LIPID MEMBRANE; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MEMBRANE STABILIZATION; MEMBRANE STRUCTURE; NONHUMAN; PHASE TRANSITION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PLEIOTROPY; PROTEIN PROTEIN INTERACTION; SOLID STATE; SURFACE PLASMON RESONANCE; SWINE;

CALORIMETRY, DIFFERENTIAL SCANNING; CELL MEMBRANE; IMIDAZOLIDINES; LIPOSOMES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PERMEABILITY; PHOSPHOCREATINE; PHOSPHOLIPIDS; SURFACE PLASMON RESONANCE;

EID: 84865073482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043178     Document Type: Article

References (82)

1. Wyss M, Kaddurah-Daouk R, (2000) Creatine and creatinine metabolism. Physiol Rev 80: 1107-1213.
2. Wallimann T, Tokarska-Schlattner M, Neumann D, Epand RM, Epand RF, et al. (2007) The phospho-creatine circuit: Molecular and cellular physiology of creatine kinases, sensitivity to free radicals and enhancement by creatine supplementation. In: Saks VA, editor. Molecular systems bioenergetics Energy for life. Weinheim: Wiley-VCH. 195-264.
3. Wallimann T, (2007) Introduction- creatine: cheap ergogenic supplement with great potential for health and disease. Subcell Biochem 46: 1-16.
4. Wyss M, Braissant O, Pischel I, Salomons GS, Schulze A, et al. (2007) Creatine and creatine kinase in health and disease- a bright future ahead? Subcell Biochem 46: 309-334.
5. Wallimann T, Tokarska-Schlattner M, Schlattner U, (2011) The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40: 1271-1296.
6. Brosnan JT, Brosnan ME, (2007) Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr 27: 241-261.
7. Harris RC, Soderlund K, Hultman E, (1992) Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci (Lond) 83: 367-374.
8. Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, et al. (1993) Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond) 84: 565-571.
9. Hespel P, Eijnde BO, Derave W, Richter EA, (2001) Creatine supplementation: exploring the role of the creatine kinase/phosphocreatine system in human muscle. Can J Appl Physiol 26 Suppl: S79-102.
10. Hespel P, Derave W, (2007) Ergogenic effects of creatine in sports and rehabilitation. Sub-Cellular Biochemistry 46: 245-259.
11. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5: 347-350.
12. Braegger CP, Schlattner U, Wallimann T, Utiger A, Frank F, et al. (2003) Effects of creatine supplementation in cystic fibrosis: results of a pilot study. J Cyst Fibros 2: 177-182.
13. NINDS-NET-PD-Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671.
14. Hass CJ, Collins MA, Juncos JL, (2007) Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair 21: 107-115.
15. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR, (2008) Functions and effects of creatine in the central nervous system. Brain Research Bulletin 76: 329-343.
16. Schlattner U, Tokarska-Schlattner M, Wallimann T, (2006) Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 1762: 164-180.
17. Speer O, Neukomm LJ, Murphy RM, Zanolla E, Schlattner U, et al. (2004) Creatine transporters: a reappraisal. Mol Cell Biochem 256-257: 407-424.
18. Saks V, Guzun R, Timohhina N, Tepp K, Varikmaa M, et al. (2010) Structure-function relationships in feedback regulation of energy fluxes in vivo in health and disease: mitochondrial interactosome. Biochim Biophys Acta 1797: 678-697.
19. Miller K, Halow J, Koretsky AP, (1993) Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am J Physiol 265: C1544-1551.
20. Lenz H, Schmidt M, Welge V, Kueper T, Schlattner U, et al. (2007) Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology. Mol Cell Biochem 306: 153-162.
21. Deldicque L, Atherton P, Patel R, Theisen D, Nielens H, et al. (2008) Effects of resistance exercise with and without creatine supplementation on gene expression and cell signaling in human skeletal muscle. Journal of Applied Physiology 104: 371-378.
22. Young JF, Larsen LB, Malmendal A, Nielsen NC, Straadt IK, et al. (2010) Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabonomics and proteomics. J Int Soc Sports Nutr 7: 9.
23. Hosamani R, Ramesh SR, (2010) Muralidhara (2010) Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicty in Drosophila melanogaster supplemented with creatine. Neurochemical Research 35: 1402-1412.
24. Wallimann T, Eppenberger HM, (1973) Properties of arginine kinase from Drosophila melanogaster. European Journal of Biochemistry 38: 180-184.
25. Martin KJ, Winslow ER, Kaddurah-Daouk R, (1994) Cell cycle studies of cyclocreatine, a new anticancer agent. Cancer Res 54: 5160-5165.
26. Schimmel L, Khandekar VS, Martin KJ, Riera T, Honan C, et al. (1996) The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. Anticancer Res 16: 375-380.
27. Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, et al. (2001) Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer 94: 513-519.
28. Lillie JW, O'Keefe M, Valinski H, Hamlin HA Jr, Varban ML, et al. (1993) Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. Cancer Res 53: 3172-3178.
29. Miller EE, Evans AE, Cohn M, (1993) Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci U S A 90: 3304-3308.
30. Annesley TM, Walker JB, (1977) Cyclocreatine phosphate as a substitute for creatine phosphate in vertebrate tissues. Energistic considerations. Biochem Biophys Res Commun 74: 185-190.
31. Kristensen CA, Askenasy N, Jain RK, Koretsky AP, (1999) Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies. Br J Cancer 79: 278-285.
32. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, et al. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157: 142-149.
33. Kurosawa Y, Degrauw TJ, Lindquist DM, Blanco VM, Pyne-Geithman GJ, et al. (2012) Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. J Clin Invest (in press).
34. Meyer LE, Machado LB, Santiago AP, da-Silva WS, De Felice FG, et al. (2006) Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. J Biol Chem 281: 37361-37371.
35. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, et al. (1997) The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 414: 253-257.
36. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T, (2003) Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J Biol Chem 278: 17760-17766.
37. Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, et al. (2004) Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 15: 610-617.
38. Lawler JM, Barnes WS, Wu G, Song W, Demaree S, (2002) Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290: 47-52.
39. Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, et al. (2006) Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med 40: 837-849.
40. Guidi C, Potenza L, Sestili P, Martinelli C, Guescini M, et al. (2008) Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochimica et Biophysica Acta 1780: 16-26.
41. Fimognari C, Sestili P, Lenzi M, Cantelli-Forti G, Hrelia P, (2009) Protective effect of creatine against RNA damage. Mutat Res 670: 59-67.
42. Deldicque L, Theisen D, Bertrand L, Hespel P, Hue L, et al. (2007) Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways. Am J Physiol Cell Physiol 293: C1263-1271.
43. Ceddia RB, Sweeney G, (2004) Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells. J Physiol 555: 409-421.
44. Ponticos M, Lu QL, Morgan JE, Hardie DG, Partridge TA, et al. (1998) Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. Embo J 17: 1688-1699.
45. Ingwall JS, (2002) Is creatine kinase a target for AMP-activated protein kinase in the heart? J Mol Cell Cardiol 34: 1111-1120.
46. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, et al. (2006) Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 281: 32207-32216.
47. Zucchi R, Poddighe R, Limbruno U, Mariani M, Ronca-Testoni S, et al. (1989) Protection of isolated rat heart from oxidative stress by exogenous creatine phosphate. J Mol Cell Cardiol 21: 67-73.
48. Konorev EA, Medvedeva NV, Dzhaliashvili IV, Stepanov VA, Saks VA, (1991) [Membranotropic effect of phosphocreatine and its structural analogs]. Biokhimiia 56: 1701-1709.
49. Saks VA, Strumia E, (1993) Phosphocreatine: molecular and cellular aspects of the mechanisms of cardioprotective action. Current Therapeutic Research, Clinical and Experimental 53: 565-598.
50. Chen JH, Wu YV, DeCarolis P, O'Connor R, Somberg CJ, et al. (2008) Resolution of creatine and phosphocreatine 1H signals in isolated human skeletal muscle using HR-MAS 1H NMR. Magn Reson Med 59: 1221-1224.
51. Schroder L, Schmitz C, Bachert P, (2004) Molecular dynamics and information on possible sites of interaction of intramyocellular metabolites in vivo from resolved dipolar couplings in localized 1H NMR spectra. J Magn Reson 171: 213-224.
52. Schlattner U, Wallimann T, (2000) Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding. J Biol Chem 275: 17314-17320.
53. Li PK, Lee JT, Li CS, Deshpande G, (1982) Improved method for determining erythrocyte creatine by the diacetyl-alpha-naphthol reaction: elimination of endogenous glutathione interference. Clin Chem 28: 92-96.
54. Schlattner U, Wallimann T, (2000) A quantitative approach to membrane binding of human ubiquitous mitochondrial creatine kinase using surface plasmon resonance. J Bioenerg Biomembr 32: 123-131.
55. Heller H, Schaefer M, Schulten K, (1993) Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid crystal phase. J Phys Chem 97: 8343-8360.
56. Schlattner U, Gehring F, Vernoux N, Tokarska-Schlattner M, Neumann D, et al. (2004) C-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine kinase. J Biol Chem 279: 24334-24342.
57. Tokarska-Schlattner M, Boissan M, Munier A, Borot C, Mailleau C, et al. (2008) The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J Biol Chem 283: 26198-26207.
58. Schlattner U, Wallimann T, (2003) Interaction proteomics with surface plasmon resonance spectroscopy: Membrane interaction of mitochondrial creatine kinase. Recent Res Devel in Biol Chem 1: 93-98.
59. Dubinnyi MA, Lesovoy DM, Dubovskii PV, Chupin VV, Arseniev AS, (2006) Modeling of 31P-NMR spectra of magnetically oriented phospholipid liposomes: A new analytical solution. Solid State Nucl Magn Reson 29: 305-311.
60. Lee SK, Lee BM, (1997) Oxidation of erythrocyte protein and lipid, and hemolysis in rabbit red blood cells treated with benzo[a]pyrene or adriamycin. J Toxicol Environ Health 51: 557-569.
61. Tokarska-Schlattner M, Dolder M, Gerber I, Speer O, Wallimann T, et al. (2007) Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. Biochim Biophys Acta 1767: 1276-1284.
62. Ronca G, Ronca-Testoni S, Conte A, Zucchi R, Limbruno U,et al. Creatine phosphate and protection from peroxidative damage. In: Tronconi L, Saks V, editors; 1989; Pavia, Italy. 61-71.
63. Hespel P, Richter EA, (1990) Glucose uptake and transport in contracting, perfused rat muscle with different pre-contraction glycogen concentrations. J Physiol 427: 347-359.
64. van Schaftingen E, Gerin I, (2002) The glucose-6-phosphatase system. Biochem J 362: 513-532.
65. Rayburn JR, Bantle JA, Qualls CW Jr, Friedman M, (1995) Protective effects of glucose-6-phosphate and NADP against alpha-chaconine-induced developmental toxicity in Xenopus embryos. Food Chem Toxicol 33: 1021-1025.
66. Sebring LA, Huxtable RJ, (1986) Low affinity binding of taurine to phospholiposomes and cardiac sarcolemma. Biochim Biophys Acta 884: 559-566.
67. Lombardini JB, Prien SD, (1983) Taurine binding by rat retinal membranes. Exp Eye Res 37: 239-250.
68. van Meer G, (2005) Cellular lipidomics. Embo J 24: 3159-3165.
69. Brumm T, Mops A, Dolainsky C, Bruckner S, Bayerl TM, (1992) Macroscopic orientation effects in broadline NMR-spectra of model membranes at high magnetic field strength: A method preventing such effects. Biophys J 61: 1018-1024.
70. Qiu X, Mirau PA, Pidgeon C, (1993) Magnetically induced orientation of phosphatidylcholine membranes. Biochim Biophys Acta 1147: 59-72.
71. Sanders CR, Hare BJ, Howard K, Prestegard JH, (1994) Magnetically-oriented phospholipid micelles as a tool for the study of membrane-associated molecules. Prog NMR Spectrosc 26: 421-444.
72. Blomgren K, Hagberg H, (2006) Free radicals, mitochondria, and hypoxia-ischemia in the developing brain. Free Radic Biol Med 40: 388-397.
73. Pacher P, Schulz R, Liaudet L, Szabo C, (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310.
74. Simonian NA, Coyle JT, (1996) Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36: 83-106.
75. Butterfield DA, Lauderback CM, (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060.
76. Beal MF, (2002) Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32: 797-803.
77. Rodriguez M, Cai WJ, Kostin S, Lucchesi BR, Schaper J, (2005) Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 38: 723-733.
78. Anyukhovsky EP, Javadov SA, Preobrazhensky AN, Beloshapko GG, Rosenshtraukh LV, et al. (1986) Effect of phosphocreatine and related compounds on the phospholipid metabolism of ischemic heart. Biochem Med Metab Biol 35: 327-334.
79. Ruda M, Samarenko MB, Afonskaya NI, Saks VA, (1988) Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction. Am Heart J 116: 393-397.
80. Sharov VG, Afonskaya NI, Ruda MY, Cherpachenko NM, Pozin E, et al. (1986) Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action. Biochem Med Metab Biol 35: 101-114.
81. Sharov VG, Saks VA, Kupriyanov VV, Lakomkin VL, Kapelko VI, et al. (1987) Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic resonance studies. J Thorac Cardiovasc Surg 94: 749-761.
82. Nabuurs C, Huijbregts B, Wieringa B, Hilbers CW, Heerschap A, (2010) 31P saturation transfer spectroscopy predicts differential intracellular macromolecular association of ATP and ADP in skeletal muscle. J Biol Chem 285: 39588-39596.